Divi's Laboratories files SEBI Regulation 31(4) disclosure under Substantial Acquisition of Shares and Takeovers Regulations

M&A / JV 6 Jul 2026 · Filed / open· ✓ Verified

The disclosure was filed with NSE under the SEBI Takeover Regulations requiring substantial acquirers to inform the exchange and public. Regulation 31(4) mandates disclosure once a threshold of 25% voting shares is crossed, triggering potential open-offer liability. The specific acquirer identity, shareholding percentage, consideration, and deal structure are contained in the full disclosure document but not publicly summarized in the headline notice.

Why it mattersRegulation 31(4) disclosures are mandatory when an acquirer breaches 25% or specified shareholding thresholds; the filing triggers open-offer obligations and cooling-off period scrutiny under SEBI takeover rules, requiring partners to verify the offer structure, timing and exemption claims.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals